GlobeNewswire·Nov 8, 2025, 11:00 AM ET

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

JBIO

Jade Biosciences presented two posters on its investigational antibody JADE101 at the ASN Kidney Week 2025 conference.
JADE101 is a selective anti-APRIL monoclonal antibody designed for the treatment of immunoglobulin A nephropathy (IgAN).
The company is currently conducting a Phase 1 healthy volunteer trial, with interim data expected in the first half of 2026 to define dosing for future IgAN patient studies.
Preclinical non-human primate (NHP) data showed JADE101 was well-tolerated with no observed adverse effect level established at the highest tested dose.
JADE101 demonstrated no off-target binding across 6,000+ human proteins, no tissue cross-reactivity, and no cytokine release in human blood assays.
Treatment in NHPs resulted in reversible reductions in serum IgA (55–68%) and IgM (62–75%), with levels returning to baseline after clearance.
JADE101 preserved vaccination responses in NHPs, indicating it is not broadly immunosuppressive despite lowering immunoglobulin levels.
Translational modeling confirmed that in vitro APRIL binding affinity predicts in vivo IgA-lowering potency in both NHPs and humans.
Biomarker responses in healthy volunteers were found to be highly consistent with those in IgAN patients, supporting their use for dose selection.
High levels of APRIL suppression correlated with the largest reductions in proteinuria and highest rates of clinical remission in IgAN patients.
JADE101 features a differentiated pharmacokinetic profile with a serum half-life of approximately 27 days, enabling potential infrequent subcutaneous dosing.
Jade Biosciences' pipeline also includes JADE201 (anti-BAFF-R) and JADE-003, both currently in preclinical development.